{"id":"W4405998503","doi":"10.1016/s2213-2600(24)00411-9","title":"Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","year":2025,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Manchester Clinical Research Facility; National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; KU Leuven; Fonds Wetenschappelijk Onderzoek; Department of Health and Social Care; National Institute for Health and Care Research; Insmed; Manchester Biomedical Research Centre; Vlaamse regering; Vertex Pharmaceuticals; Cystic Fibrosis Trust; Mylan; Deutsche Forschungsgemeinschaft; Arrowhead Pharmaceuticals; Koning Boudewijnstichting; Cystic Fibrosis Foundation Therapeutics; AstraZeneca; European Respiratory Society; American Thoracic Society","keywords":"Ivacaftor; Medicine; Cystic fibrosis; Evening; Spirometry; Cystic fibrosis transmembrane conductance regulator; Internal medicine; Physical therapy; Asthma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.02511107,0.001591775,0.009514973,0.00148306,0.0005065845,0.0002379631,0.001085689,0.0006588196,0.0006544115],"category_scores_gemma":[0.05688297,0.0009813056,0.0005439475,0.001613329,0.002102957,0.0007275062,0.0005238696,0.002291932,0.00003007032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000609608,"about_ca_system_score_gemma":0.001024046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007671079,"about_ca_topic_score_gemma":0.00005784184,"domain_scores_codex":[0.9810879,0.007033177,0.004997056,0.002388261,0.002468213,0.002025397],"domain_scores_gemma":[0.954046,0.03990958,0.002154438,0.002376937,0.0004285256,0.001084546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8088093,0.0009820809,0.01234547,0.0007731501,0.004944376,0.0005518671,0.0005919214,0.00005764688,0.07955119,0.0003040064,0.0445468,0.04654222],"study_design_scores_gemma":[0.7605293,0.004746579,0.1356493,0.004649605,0.003762255,0.00003763349,0.001344176,0.000196699,0.00322979,0.0004267435,0.08433884,0.001089122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9568615,0.02681413,0.0003318637,0.002734084,0.0002615247,0.01008755,0.00158102,0.000297055,0.001031272],"genre_scores_gemma":[0.9804651,0.002987005,0.002620818,0.003079231,0.007133857,0.001631017,0.0005344602,0.0002418142,0.001306689],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1233038,"threshold_uncertainty_score":0.999683,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08325670678336557,"score_gpt":0.407447650453088,"score_spread":0.3241909436697225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}